Cencora's Corey Ford Discusses the Future of the Inflation Reduction Act
February 29th 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now.
Cencora VP of Reimbursement & Policy Insights Discusses Implications of the Inflation Reduction Act
February 28th 2024In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement, Policy Insights, Cencora, provides a look at his recent webinar focused on the implications of the Inflation Reduction Act.
FDA Grants Priority Review to Epkinly for Relapsed/Refractory Follicular Lymphoma
February 27th 2024Epkinly (epcoritamab-bysp), a subcutaneously administered, T-cell engaging, bispecific antibody, was previously granted Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory follicular lymphoma following two or more prior lines of therapy.
Dupixent sBLA Gets FDA Priority Review for Treatment of COPD With Type 2 Inflammation
February 23rd 2024Trial data show Dupixent is the first and only novel biologic drug to significantly improve lung function and reduce severe acute exacerbations in adults with uncontrolled chronic obstructive pulmonary disease.
First-in-Class Novel Therapy for Chronic Myelomonocytic Leukemia Granted FDA Orphan Drug Designation
February 22nd 2024Immune-Onc Therapeutics’ IO-202 is currently being analyzed as a monotherapy and in combination for patients with relapsed/refractory acute myeloid leukemia with monocytic differentiation or chronic myelomonocytic leukemia.
FDA Grants Priority Review to Novel Bispecific Antibody for Multiple Myeloma
February 21st 2024Regeneron Pharmaceuticals’ linvoseltamab is currently in clinical development to treat adult patients with relapsed/refractory multiple myeloma who experienced disease progression following prior administration of at least three therapies.